MENU

Fox Chase Cancer Center News

April 3, 2012

New Compound Targets Key Mechanism Behind Lymphoma

CHICAGO, IL (April 3, 2012) – Scientists at Fox Chase Cancer Center in Philadelphia have come one step closer to developing the first treatment to target a key pathway in lymphoma.  The new findings will be announced at the AACR Annual Meeting 2012 on Tuesday, April 3.

April 3, 2012

Scientists at Fox Chase Discover Link between Estrogen and Tobacco Smoke

CHICAGO, IL (April 3, 2012) – The hormone estrogen may help promote lung cancer— including compounding the effects of tobacco smoke on the disease—pointing towards potential new therapies that target the hormone metabolism, according to new research presented at the AACR Annual Meeting 2012 on Tuesday, April 3 by scientists at Fox Chase Cancer Center in Philadelphia.

"This research provides the link between estrogen and tobacco smoke," says study author Jing Peng, PhD, postdoctoral associate in the lab of Margie L. Clapper, PhD, also a co-author on the paper.

Sue Coady, RN
April 2, 2012

Fox Chase Cancer Center Nurse Acknowledged with DAISY Award

PHILADELPHIA (April 2, 2012) — Registered nurse Sue Coady is the first Fox Chae nurse to receive the DAISY Award for Extraordinary Nurses. The award celebrates the clinical skill and compassionate care given by nurses in all types of settings.

April 2, 2012

Researchers Uncover New Clues to the Development of Blood and Other Cancers

CHICAGO, IL (April 2, 2012) – Latest findings from Fox Chase Cancer Center reveal that targeting inflammatory pathways may lead to new therapies.

April 2, 2012

Researchers Identify a Gene that Predicts Recurrence in Squamous Cell Carcinoma of the Head and Neck

CHICAGO, IL (April 2, 2012) – Results could lead to personalized treatment strategies for patients with this type of cancer.

April 2, 2012

New Boost for Pancreatic Cancer Therapy

CHICAGO, IL (April 2, 2012) – Scientists at Fox Chase Cancer Center are developing a new way to treat pancreatic cancer by boosting the effects of gemcitabine (Gemzar)—the chemotherapy drug that is considered standard therapy for the disease. 

April 1, 2012

The Protein Survivin Could be a Useful Biomarker for Pancreatic Cancer

CHICAGO, IL (April 1, 2012) —  New research from scientists at Fox Chase Cancer Center shows that a protein called survivin could be a useful tool in understanding pancreatic cancer—particularly for identifying which subsets of patients will most likely respond to treatment. The scientists found that patients who underwent different treatment regimens, following surgery, had different levels of survivin and experienced different lengths of disease-free survival.

April 1, 2012

Fox Chase Scientists Identify Key Protein Players in Hard-to-Treat Breast Cancers

CHICAGO, IL (April 1, 2012)—At the time of diagnosis, the majority of breast cancers are categorized as estrogen-receptor positive, or hormone sensitive, which means their cancerous cells may need estrogen to grow. Patients with this type of cancer often respond favorably to treatments called aromatase inhibitors, like tamoxifen, which cause cell death by preventing estrogen from reaching the cancerous cells. Over time, however, the disease often becomes resistant to estrogen deprivation from the drugs—making treatment options more limited. New findings by researchers from Fox Chase Cancer Center identify a pair of proteins that could play a crucial role in restoring treatment sensitivity to these resistant cancerous cells—possibly leading to more treatment options in the future.

Pages

Connect with Fox Chase